At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 202 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Pazopanib and Erlotinib for Non Small Cell Lung Cancer. Completed, enrolled 202 participants across 8 sites.
Detailed Summary
This randomized, placebo-controlled, Phase II trial will compare the combination of erlotinib with pazopanib (providing concurrent EGFR and VEGFR inhibition) with erlotinib alone in the second- or third-line treatment of patients with advanced NSCLC. This study will be conducted though the Sarah Cannon Research Consortium, a community-based clinical trial network.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline, OSI Pharmaceuticals
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionApr 2014
Study CompletionJun 2014
TodayJul 2026
First PostedDec 8, 2009
Enrollment StartJan 1, 2010
Primary CompletionApr 1, 2014
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.6 years ago
Interventions
Pazopanibdrug
Pazopanib: 600 mg orally daily
Erlotinibdrug
Erlotinib: 150 mg orally daily